earliest
drug
deriv
natur
product
compound
could
easili
made
chemic
mani
molecul
still
use
today
includ
aspirin
steroid
antibiot
produc
microorgan
light
problem
bring
new
drug
market
mani
research
consid
screen
food
drug
administr
fda
drug
repurpos
lower
risk
de
novo
drug
search
specif
molecul
novel
drug
target
may
perceiv
unrealist
especi
emerg
diseas
thu
approxim
compound
use
clinic
reinvestig
see
treatment
could
provid
difficult
treat
condit
search
approv
drug
new
purpos
aid
commerci
avail
compil
drug
approv
fda
prestwick
chemic
librari
librari
pharmacolog
activ
compound
specif
librari
assembl
variou
purpos
target
interact
kinas
drug
repurpos
hub
http
wwwbroadinstituteorgrepurpos
consist
reliabl
physic
sourc
approv
drug
well
virtual
librari
describ
characterist
certainli
help
identifi
new
use
exist
also
varieti
publicli
avail
resourc
assist
repurpos
includ
fine
common
reason
repurpos
approv
drug
alreadi
test
safeti
human
mean
enter
clinic
discuss
section
mani
older
drug
even
known
seriou
side
effect
inde
reintroduc
clinic
purpos
beyond
origin
indic
section
highlight
despit
disastr
first
introduct
withdraw
clinic
last
centuri
thalidomid
deriv
use
treat
varieti
seriou
health
threat
drug
design
treat
mani
indic
introduc
cancer
thalidomid
stori
illustr
even
drug
seriou
known
side
effect
success
also
exampl
simpl
chang
structur
gener
much
activ
molecul
show
repurpos
aid
design
novel
drug
section
mani
exampl
given
drug
found
new
use
far
initi
indic
rapid
applic
effect
antibiot
bacteri
infect
greatli
decreas
length
hospit
risk
rise
bacteria
well
pauciti
novel
antibiot
led
mani
effort
make
current
arsen
potent
combin
older
antibiot
section
highlight
strategi
well
effort
combin
antibiot
agent
target
bacteri
block
bacteri
enzym
export
degrad
antibiot
case
simpli
chang
mode
applic
drug
suffici
enhanc
activ
anoth
impetu
repurpos
find
treatment
emerg
infect
target
host
cell
pathway
rather
infecti
agent
directli
way
complement
antibiot
antivir
drug
enhanc
host
cell
resist
mechan
thu
becom
activ
promis
area
discuss
section
one
drive
forc
abil
pathogen
quickli
develop
resist
target
inhibitor
exampl
drug
resist
develop
two
four
influenza
activ
host
immun
system
especi
import
look
new
way
treat
chronic
infect
tuberculosi
tb
new
way
must
also
found
treat
virus
includ
ebola
develop
mechan
evad
host
immun
system
paradox
repurpos
wave
occur
clinic
success
antivir
daa
hepat
c
viru
shown
power
high
throughput
screen
coupl
ration
section
devot
difficulti
repurpos
drug
natur
product
older
drug
may
repurpos
overcom
mani
approv
drug
low
solubl
lack
specif
may
requir
unrealist
dose
use
beyond
initi
target
section
dosag
may
well
toler
trial
conduct
use
healthi
subject
case
anim
studi
healthi
infect
may
achiev
clinic
patient
clinic
field
hospit
sick
present
comorbid
burn
cancer
ebola
emerg
infect
victim
fragil
patient
thu
like
suffer
side
effect
high
dose
collabor
medicin
chemist
earli
stage
develop
insur
specif
potent
therapi
test
section
exampl
show
deriv
older
drug
better
pharmaceut
properti
select
bring
new
treatment
clinic
deriv
add
continu
expand
drug
pantheon
mani
current
use
thalidomid
repres
perhap
spectacular
exampl
old
drug
assum
new
thalidomid
tabl
origin
introduc
chemi
avail
counter
sever
european
countri
treat
insomnia
morn
sick
drug
approv
young
examin
assign
thalidomid
applic
note
defect
safeti
profil
especi
concern
sever
peripher
neuriti
report
possibl
side
thu
even
without
teratogen
test
thalidomid
potenti
caus
danger
side
effect
clear
thalidomid
withdrawn
worldwid
becam
notori
caus
sever
birth
defect
drug
associ
side
effect
includ
rash
tremor
hypothyroid
hypocalcemia
hyperkalemia
toxic
epiderm
necrolysi
patient
would
seem
doom
mere
cautionari
tale
histori
pharmaci
yet
thalidomid
soon
rose
ash
use
treat
skin
lesion
granuloma
associ
leprosi
today
thalidomid
part
treatment
hanson
diseas
curious
abil
bind
protein
involv
limb
outgrowth
believ
root
teratogen
effect
may
also
enabl
control
growth
multipl
myeloma
potent
deriv
lenalidomid
pomalidomid
tabl
approv
fda
treat
multipl
mantl
cell
lymphoma
myelodysplast
syndrom
associ
delet
abnorm
thalidomid
deriv
inhibit
secret
tumor
necrosi
factor
tnf
inflammatori
direct
indirect
effect
led
mani
test
abil
eas
inflamm
low
dose
thalidomid
mgday
allevi
symptom
patient
crohn
diseas
refractori
mani
thalidomid
also
allevi
cytokin
storm
induc
bacteri
anim
studi
indic
might
use
treatment
aneurysm
traumat
brain
specif
inhibitor
allevi
sever
diseas
associ
overexpress
psoriasi
lupu
erythematosu
rheumatoid
lenalidomid
treatment
may
even
restor
color
gray
might
relat
effect
regul
hair
note
therapi
tyrosin
kinas
may
also
affect
hair
color
repigment
case
darken
hair
also
seen
therapi
inhibitor
author
describ
repigment
side
effect
possibl
clinic
marker
success
recent
govern
support
led
mani
approv
drug
test
applic
far
beyond
initi
use
exampl
drug
antituss
sed
analges
antipyret
antiarthrit
anesthet
antidiabet
muscl
relax
immunosuppress
antibiot
antiepilept
cardioprotect
antihypertens
erectil
function
enhanc
angina
reliev
properti
may
use
adjuv
therapi
exampl
repurpos
drug
test
select
group
patient
enter
clinic
trial
shown
tabl
effort
reus
exist
drug
novel
therapi
especi
import
rare
diseas
patient
popul
small
justifi
major
effort
need
introduc
new
drug
altern
may
way
identifi
treatment
sever
diseas
idiopath
etiolog
tabl
indic
repurpos
may
provid
altern
treatment
psychiatr
disord
antioxid
ebselen
test
treat
bipolar
disord
patient
toler
lithium
treatment
loxapin
may
treat
irrit
associ
autism
antiinflammatori
drug
well
varieti
repurpos
compound
also
suggest
altern
treatment
schizophren
patient
includ
acetylsalicyl
acid
celecoxib
minocyclin
natur
microbi
commun
consist
complex
mixtur
bacteria
virus
fungi
organ
fight
other
domin
organ
surviv
secret
antibiot
toxin
evolv
intern
enzym
deactiv
compound
succeed
penetr
cell
wall
envelop
clinic
import
microb
survivor
battl
mean
typic
possess
power
defens
weapon
consist
array
toxin
enzym
degrad
export
antibiot
tool
deal
serum
proteas
mammalian
immun
system
face
antibiot
treatment
enzym
arsen
evolv
meet
new
challeng
past
older
antibiot
constantli
supersed
newer
one
design
evad
latest
resist
mechan
found
clinic
isol
howev
mani
compani
drop
program
develop
new
antiinfect
due
time
cost
clinic
trial
lack
new
drug
given
strong
incent
repurpos
older
antibiot
strain
combin
agent
target
sever
differ
pathway
pathogen
activ
host
cell
resist
pathway
lead
enhanc
activ
lower
chanc
develop
revert
older
antibiot
case
overcom
antibiot
resist
exampl
tb
strain
resist
current
use
drug
combin
found
part
world
one
use
tb
drug
isoniazid
inhibit
enzym
inha
block
synthesi
mycol
acid
make
cell
wall
mycobacterium
much
resist
isoniazid
prodrug
come
mutat
bacteri
enzym
requir
activ
recent
found
older
natur
product
antibiot
pyridomycin
discov
inhibit
inha
directli
thu
use
treat
infect
resist
tb
strain
surviv
lack
abil
activ
understand
mechan
action
may
also
advanc
use
pyridomycin
conjunct
combin
antibiot
agent
inhibit
toxin
effector
contribut
pathogen
also
enhanc
activ
tissu
damag
immun
activ
caus
bacteri
produc
toxin
includ
proteas
pyrolyt
toxin
superantigen
elev
tissu
cyclic
adenosin
monophosph
antibiot
addit
activ
may
lead
synergi
antagon
toxin
product
exampl
antibiot
increas
product
bacteri
toxin
staphylococcu
aureu
inhibit
protein
synthesi
clindamycin
greatli
reduc
toxin
mediat
pathogen
effect
even
death
bacteria
direct
inhibitor
bacteri
toxin
may
aid
control
symptom
use
alon
combin
discuss
next
section
patient
may
benefit
altern
applic
mode
cotreat
antibiot
compound
design
directli
target
pathway
human
cell
applic
mode
antibiot
also
affect
activ
oral
avail
prize
inpati
frequent
treat
antibiot
infus
direct
inject
inhal
drug
may
give
complet
differ
activ
inject
infus
recent
experi
pig
delet
cystic
fibrosi
transmembran
receptor
cftr
shown
aerosol
treatment
amphotericin
b
toxic
antifung
agent
formul
liposom
cholesterol
restor
airway
ph
level
author
suggest
similar
aerosol
treatment
would
help
cf
patient
mani
differ
cftr
similarli
inhal
may
also
improv
abil
interferon
treat
interferon
ifn
mechan
action
differ
abil
directli
control
origin
use
antivir
immun
activ
current
use
via
subcutan
inject
treat
chronic
granulomat
diseas
osteopetrosi
control
clinic
trial
inhal
could
control
tb
parenter
result
indic
macrophag
effect
aerosol
therapi
treatment
aerosol
well
toler
safeti
studi
patient
idiopath
pulmonari
fibrosi
declin
pulmonari
function
revers
approach
may
also
use
type
drug
may
also
benefit
chang
mode
applic
drug
show
long
term
toxic
still
prove
valuabl
use
short
period
time
exampl
mibefradil
origin
use
blood
pressur
control
withdrawn
chronic
use
slow
excret
mani
drug
caus
accumul
danger
level
liver
recent
shown
short
term
dose
mibefradil
enhanc
activ
sever
differ
cancer
note
abil
thalidomid
deriv
block
major
regul
inflammatori
respons
led
use
diseas
psoriasi
autoimmun
disord
character
cytokin
overproduct
tetracyclin
deriv
doxycyclin
aid
wound
heal
inhibit
host
metalloproteas
may
caus
tissu
doxycyclin
also
play
similar
role
control
antiinflammatori
compound
includ
nonsteroid
antiinflammatori
drug
nsaid
control
fever
aspect
cytokin
storm
sever
differ
virus
induc
ibuprofen
suggest
control
ebola
nsaid
also
improv
surviv
cancer
exampl
patient
activ
mutat
common
head
neck
cancer
predict
overal
surviv
significantli
higher
vs
vs
respect
use
nsaid
regularli
treatment
agent
target
pathogen
directli
select
resist
virus
repurpos
drug
design
inhibit
host
cell
pathway
requir
virus
activ
pathogen
respons
mechan
suggest
antivir
recent
epidem
emphas
need
wide
spectrum
oral
agent
stimul
host
antivir
pathway
earliest
protein
antivir
control
mani
expens
even
new
extend
pegyl
ifn
prepar
requir
regular
howev
smaller
antivir
compound
may
enhanc
activ
combin
small
antivir
induc
ifn
pathway
identifi
high
throughput
screen
chugai
may
provid
oral
interferon
treatment
could
complement
direct
act
antivir
daa
altern
compound
activ
sting
pathway
may
also
provid
use
adjuv
howev
mani
virus
sensit
ifn
produc
factor
interfer
ifn
gene
isg
ifn
level
uninfect
individu
typic
vanishingli
low
high
persist
presenc
ifn
andor
induc
gene
isg
may
also
complic
even
caus
diseas
atop
dermat
recent
result
indic
high
serum
level
treatment
hcv
daa
may
correl
develop
hepat
thu
sever
ifn
neutral
therapi
test
lupu
may
use
treat
diseas
character
overproduct
ifn
induc
includ
bind
ifn
inhibitor
interferon
pathway
autophagi
pathway
specif
accord
type
viru
infect
inhibitor
autophagi
may
inhibit
growth
rna
virus
reli
associ
membran
replic
picornavirus
howev
inhibitor
might
favor
lytic
growth
herp
virus
whose
replic
held
check
result
screen
drug
librari
reveal
sever
mammalian
cell
pathway
may
target
exampl
blocker
ion
channel
report
vitro
activ
japanes
enceph
human
arenavirus
lassa
exampl
fluorescein
deriv
rose
bengal
dye
approv
food
use
common
laboratori
stain
first
use
medicin
treat
ocular
infect
thank
low
toxic
rose
bengal
therapi
quickli
enter
clinic
today
topic
version
dye
test
reduc
scar
injuri
molecul
becam
even
interest
test
indic
inhibit
growth
tumor
cell
formul
clinic
trial
treat
howev
larg
amount
dye
requir
compound
serum
figur
illustr
larg
hydrophob
molecul
limit
solubl
result
trial
may
use
obtain
deriv
better
pharmaceut
characterist
design
solubl
specif
anticanc
activ
drug
ideal
candid
mani
chemotherapi
drug
requir
infus
bright
blue
compound
mitroxantron
agent
varieti
activ
limit
solubl
may
induc
nonspecif
aggreg
protein
assay
reagent
high
throughput
good
deal
time
lost
nonspecif
aggreg
mislead
activ
varieti
differ
assay
low
micromolar
mitroxantron
even
turn
preliminari
screen
identifi
inhibitor
uridyly
peptid
link
genom
coxsacki
viru
author
group
sever
differ
assay
requir
show
precipit
rna
substrat
rather
specif
inhibit
polymeras
uridylyl
reaction
ad
deterg
control
aggreg
induc
agent
may
suitabl
assay
physicochem
properti
drug
solubl
obtain
free
onlin
databas
includ
ochem
http
ochemeu
mani
drug
includ
use
chemotherapi
sever
side
effect
may
prevent
use
purpos
exampl
emetin
better
known
activ
ingredi
ipecac
syrup
bind
inhibit
varieti
also
report
select
kill
acut
myeloid
leukemia
emetin
select
ebola
minigenom
ht
assay
run
level
activ
compon
report
submicromet
activ
zika
ebola
viru
howev
emetin
caus
sever
nausea
taken
oral
inject
remain
seen
whether
emetin
side
effect
overcom
suffici
bring
clinic
indic
similarli
success
mani
ongo
trial
calcineurin
inhibitor
eg
tacrolimu
control
inflammatori
bowel
diseas
atop
dermat
rheumatoid
arthriti
autoimmun
diseas
may
limit
increas
risk
sever
infect
intrins
inhibit
pathway
essenti
control
bacteri
fungal
side
effect
may
also
limit
clinic
use
varieti
compound
suggest
treatment
seriou
viru
infect
cancer
drug
gemcitabin
inhibit
bioflavonoid
rutin
inhibit
quinin
antimalari
suggest
flavivirus
dengu
well
coronavirus
clinic
futur
treatment
depend
whether
side
effect
short
term
administr
accept
may
also
possibl
identifi
known
drug
reduc
side
effect
recent
paper
suggest
categor
drug
accord
indic
known
side
effect
one
could
identifi
drug
could
replac
box
warn
safer
one
similar
anoth
obstacl
repurpos
higher
concentr
drug
may
need
use
purpos
beyond
origin
design
high
throughput
screen
approv
drug
may
conduct
concentr
compound
screen
larger
compound
librari
done
follow
dilut
lower
concentr
secondari
assay
initi
hit
high
concentr
drug
may
differ
mechan
associ
suggest
use
human
compound
may
bind
molecul
littl
initi
determin
mechan
action
caus
side
effect
translat
human
therapi
even
molecul
suggest
specif
exampl
high
affin
coupl
receptor
found
bind
complet
unrel
molecul
phosphodiesteras
wherebi
bind
site
screen
larg
compound
librari
dock
found
mani
molecul
select
bind
specif
site
fact
bound
preferenti
differ
one
given
larger
region
protein
surfac
choos
inexpens
oral
avail
nucleotid
analog
ribavirin
favipiravir
develop
use
high
concentr
inhibit
mani
viral
rna
polymeras
differ
favipiravir
inhibit
congo
hemorrhag
fever
viru
cchf
ebola
mice
lassa
primat
model
use
ribavirin
treat
lassa
fever
howev
favipiravir
even
dose
mgkg
complet
elimin
cchf
surviv
infect
mice
sever
die
treatment
stop
macaqu
surviv
highest
dose
use
mgkg
although
favipiravir
small
solubl
compound
figur
still
high
dose
use
combin
oseltamivir
mgkg
treat
influenza
effect
dose
rang
attempt
treat
ebola
patient
epidem
high
dose
favipiravir
gday
gave
unaccept
signific
side
effect
patient
sever
ill
nucleotid
deriv
may
better
potenc
treat
caus
yet
anoth
larg
outbreak
anoth
exampl
repurpos
drug
activ
high
concentr
antimalari
drug
pyrimethamin
found
stabil
enzym
defect
howev
produc
signific
side
effect
mg
dose
requir
efficaci
phase
test
eight
human
test
gave
temporari
improv
measur
enzym
activ
one
four
patient
remain
stabl
three
continu
deterior
seven
year
initi
drug
screen
activ
form
pyrimethamin
hope
find
treatment
deadli
diseas
despit
worldwid
withdraw
market
thalidomid
approv
treat
granuloma
associ
leprosi
exampl
even
obviou
side
effect
drug
may
use
clinic
specif
purpos
thalidomid
treatment
alway
limit
side
effect
small
chang
result
much
activ
molecul
could
use
lower
dose
tabl
cours
deriv
must
go
toxic
screen
new
clinic
trial
market
take
consider
time
thalidomid
activ
deriv
approv
specif
treatment
lenalidomid
pomalidomid
similarli
small
structur
chang
may
complet
alter
spectrum
activ
antibiot
conjug
daptomycin
antibiot
target
bacteria
siderophor
mimet
gener
new
seri
antibiot
could
penetr
cell
wall
strain
acinetobact
baumannii
recent
approv
deriv
tetracyclin
tabl
also
illustr
small
structur
chang
may
enhanc
drug
specif
activ
abil
evad
resist
mechan
tetracyclin
block
elong
protein
bacteria
bind
ribosom
subunit
new
deriv
nuzyra
omadacyclin
aminomethylcyclin
design
overcom
bacteri
resist
tetracyclin
caus
bacteri
efflux
pump
tetk
tetl
tet
ribosom
protect
protein
tetm
nuzyra
use
treat
bacteri
pneumonia
caus
varieti
resist
bacteria
includ
aureu
streptococc
xerava
eravacyclin
synthet
fluorocyclin
develop
treat
infect
caus
mani
differ
enter
contrast
seysara
sarecyclin
recommend
acn
vulgari
less
activ
enter
bacteria
reduc
although
treatment
deriv
may
save
cost
compar
still
much
expens
parent
tetracyclin
repurpos
older
molecul
path
find
novel
therapi
screen
approv
drug
librari
may
effici
way
identifi
treatment
rare
emerg
diseas
perhap
best
exampl
repurpos
drug
thalidomid
despit
notori
side
effect
provid
valuabl
treatment
cancer
granuloma
associ
leprosi
tabl
illustr
mani
drug
test
use
treat
condit
beyond
origin
target
older
antibiot
may
also
repurpos
combin
activ
compound
achiev
activ
infecti
agent
howev
mani
exist
drug
poor
physicochem
properti
signific
side
effect
use
high
concentr
identifi
appropri
deriv
approv
compound
end
fastest
path
clinic
deriv
thalidomid
tetracyclin
provid
excel
exampl
rel
small
chang
drug
structur
greatli
lower
dosag
requir
alter
spectrum
activ
mean
comprehens
mani
exampl
shown
illustr
great
promis
exist
pharmacopeia
modif
thereof
treat
mani
ill
flesh
heir
